BiotechTube
GenomeKey

GenomeKey

London, United Kingdom· Est.
genomekey.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

GenomeKey, founded in 2018, is a private, pre-revenue diagnostics company tackling the global sepsis and antimicrobial resistance crises. Its core technology is an IVD device that leverages DNA sequencing and machine learning to detect, identify, and provide a full AMR profile for pathogens directly from blood samples in just hours. The company has secured non-dilutive grant funding, notably from CARB-X, and has formed a key collaboration with Oxford Nanopore Technologies to develop its platform. GenomeKey is in the development and validation stage, building towards clinical demonstrations and regulatory approval for its transformative diagnostic system.

Infectious DiseaseSepsis

Technology Platform

Next-generation IVD device integrating DNA sequencing and machine learning to detect, identify, and provide antimicrobial resistance (AMR) profiles for pathogens directly from patient blood samples in hours.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The massive, unmet need in sepsis diagnosis and antimicrobial stewardship creates a multi-billion dollar market.
Rapid, accurate diagnostics can command premium pricing by demonstrating value through improved patient outcomes, reduced hospital stays, and lower overall healthcare costs.
The platform's core technology could also be adapted for other complex infection types in the future.

Risk Factors

Key risks include failure to achieve the required clinical sensitivity and specificity in validation studies, delays or hurdles in obtaining regulatory clearance (FDA/CE), and challenges in commercial adoption against entrenched standard practices and competitors.
The pre-revenue status also implies future dilution through necessary fundraising.

Competitive Landscape

GenomeKey competes with established culture-based diagnostics, rapid molecular panels (e.g., BioFire, Luminex), and emerging next-generation sequencing solutions. Its key differentiators are the direct-from-blood workflow, comprehensive AMR profiling, and a focus on speed and cost. Success depends on outperforming these alternatives in clinical utility and ease of integration.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →